Gingerol

Gingerol

SCHEMBL2121898

CCCCCC(O)CC(=O)CCc1ccc(O)c(OC)c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
LTA4H P09960 6/20 1.00
CYP3A4 P08684 5/20 1.00
TRPV1 Q8NER1 5/20 1.00
CYP2C8 P10632 4/20 1.00
CYP2C9 P11712 4/20 1.00
CYP2B6 P20813 4/20 1.00
CYP2C19 P33261 4/20 1.00
CYP1A2 P05177 3/20 1.00
HTR1A P08908 3/20 0.98
CYP2D6 P10635 2/20 0.98
CYP2A6 P11509 2/20 0.98
CYP2E1 P05181 1/20 0.98
POLB P06746 1/20 0.72
GAA P10253 1/20 0.72
ALOX5 P09917 1/20 0.61
OR51E2 Q9H255 1/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Gingerol SCHEMBL17368634 1.00 LTA4H (1.00) LTA4HCYP3A4TRPV1CYP2C8CYP2C9
Gingerol SCHEMBL32102 1.00 LTA4H (1.00) LTA4HCYP3A4TRPV1CYP2C8CYP2C9
Gingerol SCHEMBL30767163 1.00 LTA4H (1.00) LTA4HCYP3A4TRPV1CYP2C8CYP2C9
Gingerol SCHEMBL29475335 1.00 LTA4H (1.00) LTA4HCYP3A4TRPV1CYP2C8CYP2C9
SCHEMBL17301613 0.99 LTA4H (1.00) LTA4HCYP3A4TRPV1CYP2C8CYP2C9
SCHEMBL20668234 0.99 LTA4H (1.00) LTA4HCYP3A4TRPV1CYP2C8CYP2C9
SCHEMBL17301612 0.99 LTA4H (1.00) LTA4HCYP3A4TRPV1CYP2C8CYP2C9
SCHEMBL20668179 0.99 LTA4H (1.00) LTA4HCYP3A4TRPV1CYP2C8CYP2C9
SCHEMBL4883453 0.99 LTA4H (1.00) LTA4HCYP3A4TRPV1CYP2C8CYP2C9
SCHEMBL4885722 0.99 LTA4H (1.00) LTA4HCYP3A4TRPV1CYP2C8CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 167 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119522938-A Zingiberaceae plant extract, composition thereof and pest control application thereof 成都新朝阳作物科学股份有限公司 2025-02-28 CN claimed
WO-2023064318-A1 BIPHASIC COMPOSITIONS COMPRISING ONE OR BOTH OF CARBONATE AND PHOSPHATE Natural Extraction Systems, LLC (US) 2023-04-20 WO claimed
US-20230089351-A1 METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES Natural Extraction Systems, LLC (US) 2023-03-23 US claimed
CN-113040147-B High-safety synergistic disinfectant for livestock 江苏康巴特生物工程有限公司 2022-02-11 CN claimed
WO-2021158575-A1 COMPOSITIONS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES Natural Extraction Systems, LLC (US) 2021-08-12 WO claimed
WO-2021158573-A1 METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES Natural Extraction Systems, LLC (US) 2021-08-12 WO claimed
US-20150119327-A1 DRUG SCREENING PLATFORM FOR RETT SYNDROME THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2015-04-30 US claimed
EP-2841067-A2 A DRUG SCREENING PLATFORM FOR RETT SYNDROME The Regents of The University of California (US) 2015-03-04 EP claimed
WO-2013163455-A2 A DRUG SCREENING PLATFORM FOR RETT SYNDROME THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2013-10-31 WO claimed
EP-2578222-A1 Plant extract composition Lanwehr, Christoph Alexander Bernhard (DE) 2013-04-10 EP claimed
WO-2008080980-A1 MEDICINAL COMPOSITION FOR TREATING ANIMAL SKIN COMPRISING A WOUND HEALING AGENT AND A DETERRENT FRANKE PATRICK (DE) 2008-07-10 WO claimed
JP-9176002-A None JP disclosed
US-12588699-B2 Aerosol-generating substrate PHILIP MORRIS PRODUCTS S.A. (CH) 2026-03-31 US disclosed
EP-4665315-A1 METHODS OF PREPARATION OF ZINGERONE, COMPOSITIONS COMPRISING ZINGERONE, AND USES THEREFOR Evithe Limited (NZ) 2025-12-24 EP disclosed
US-20250255927-A1 COMPOSITIONS AND METHODS FOR ALLEVIATING ADVERSE EFFECTS FROM RESPONSIBLE ALCOHOL CONSUMPTION CHEERS HEALTH, INC. 2025-08-14 US disclosed
WO-2000002569-A2 COMPOSITIONS FOR THE TREATMENT OF ATHEROSCLEROSIS AND RELATED CONDITIONS DALIDAR PHARMA ISRAEL (1995) LTD. (IL) 2000-01-20 WO disclosed
EP-0631474-B1 CYCLIC ANTI-TUMOR PROMOTER COMPOUNDS, COMPOSITIONS AND METHODS FOR PRODUCTION AND USE UNIV HAWAII (US) 1998-12-23 EP disclosed
JP-H09176002-A GINGEROL-CONTAINING AGENT FOR SUPPRESSING SYNTHESIS OF PROTEIN OF HSP27 FAMILY KUREHA CHEM IND CO LTD 1997-07-08 JP disclosed
US-5349112-A Cyclic anti-tumor promoter compounds, compositions and methods for production and use UNIVERSITY OF HAWAII (US) 1994-09-20 US disclosed
US-5276217-A Anticarcinogenic, analog of sarcophytol A, carbocyclic compound with 6-14 ring carbons UNIVERSITY OF HAWAII (US) 1994-01-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230089351-A1 METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES FABP2, FABP4, GUSB LTA4H 753/4885CYP3A4 3571/4885TRPV1 1110/4885
US-20150119327-A1 DRUG SCREENING PLATFORM FOR RETT SYNDROME GRIN2A, GRIN1, GRIN2B LTA4H 3911/4885CYP3A4 4856/4885TRPV1 1320/4885
US-12588699-B2 Aerosol-generating substrate CCT5, PRUNE1, DSTN LTA4H 3290/4885CYP3A4 1241/4885TRPV1 4202/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.